Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Selling and marketing | 15,195 | 26,035 |
| Research and development | 8,351 | 16,442 |
| Research and development - related parties | — | — |
| General and administrative | 7,277 | 15,481 |
| Transaction costs | — | - |
| Total operating expenses | 31,974 | 60,003 |
| (Loss) income from operations | (2,240)) | 302) |
| Other (loss) income, net: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s G&A?
- Gyre Therapeutics, Inc. (GYRE) reported G&A of $7.87M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s G&A changed year-over-year?
- Gyre Therapeutics, Inc.'s G&A increased by 8.1% year-over-year, from $7.28M to $7.87M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s G&A has grown at a 5.2% compound annual growth rate (CAGR), from $18.96M to $23.25M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Gyre Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude